SCHEMBL6360728

SCHEMBL6360728

N#Cc1cccc(-c2ccccc2)c1NC(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 1/20 0.45
GRM5 P41594 1/20 0.44
KDM4E B2RXH2 5/20 0.43
GAA P10253 3/20 0.43
CXCR2 P25025 1/20 0.42
ALDH1A1 P00352 3/20 0.41
HPGD P15428 2/20 0.41
GALR3 O60755 1/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
LMNA P02545 1/20 0.40
PTPN5 P54829 1/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNB4 P30926 1/20 0.39
CHRNA3 P32297 1/20 0.39
CHRNA4 P43681 1/20 0.39
GRIA2 P42262 1/20 0.39
GRIA4 P48058 1/20 0.39
USP2 O75604 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22979609 0.78 TSHR (0.48) KDM4EGAACXCR2ALDH1A1MEN1
SCHEMBL21995607 0.77 KMT2A (0.45) KDM4EGAACXCR2ALDH1A1MEN1
SCHEMBL22979896 0.77 GAA (0.43) KDM4EGAACXCR2ALDH1A1HPGD
SCHEMBL22979056 0.77 GAA (0.41) KDM4EGAACXCR2ALDH1A1MEN1
SCHEMBL17796920 0.76 ALDH1A1 (0.52) ESR2ALDH1A1HPGDMEN1KMT2A
SCHEMBL4845202 0.75 ESR2 (0.48) ESR2KDM4EGAAALDH1A1HPGD
SCHEMBL3972345 0.75 LMNA (0.54) KDM4EALDH1A1HPGDMEN1KMT2A
Bicarbonate SCHEMBL7256332 0.75 ALDH1A1 (0.49) ESR2KDM4EGAAALDH1A1HPGD
SCHEMBL25264151 0.75 FOLH1 (0.49) ESR2KDM4EGAAALDH1A1HPGD
SCHEMBL31212991 0.75 FOLH1 (0.49) ESR2KDM4EGAAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050239841-A1 New compounds BIOVITRUM AB (SE) 2005-10-27 US disclosed
WO-2005051381-A1 Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R) BIOVITRUM AB (SE) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239841-A1 New compounds MCHR1, NPY1R, HCRTR1 ESR2 1119/4885GRM5 300/4885KDM4E 3911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.